Inicio > BIGG > Resultado de la búsqueda

    Resultados: 3

    Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology

    Queirolo, P; Cinquini, M; Argenziano, G; Bassetto, F; Bossi, P; Boutros, A; Clemente, C; Del Vecchio, M; Pennachioli, E; Peris, K; Quaglino, P; Reali, A; Zalaudek, I; Spagnolo, F.
    ESMO open; 9 (5), 2024
    Cutaneous squamous cell carcinoma (CSCC) accounts for ∼20%-25% of all skin tumors. Its precise incidence is often challenging to determine due to limited statistics and its incorporation with mucosal forms. While most cases have a favorable prognosis, challenges arise in patients presenting with locall...
    Neoplasias Cutáneas/diagnóstico, Carcinoma de Células Escamosas/tratamiento farmacológico, Queratinocitos/efectos de los fármacos, Antineoplásicos Inmunológicos, Nivolumab
    Texto completo

    Systemic therapy for melanoma: ASCO guideline update

    Seth, Rahul; Agarwala, Sanjiv S; Messersmith, Hans; Alluri, Krishna C; Ascierto, Paolo A; Atkins, Michael B; Bollin, Kathryn; Chacon, Matias; Davis, Nancy; Faries, Mark B; Funchain, Pauline; Gold, Jason S; Guild, Samantha; Gyorki, David E; Kaur, Varinder; Khushalani, Nikhil I; Kirkwood, John M; McQuade, Jennifer Leigh; Meyers, Michael O; Provenzano, Anthony; Robert, Caroline; Santinami, Mario; Sehdev, Amikar; Sondak, Vernon K; Spurrier, Gilliosa; Swami, Umang; Truong, Thach-Giao; Tsai, Katy K; van Akkooi, Alexander; Weber, Jeffrey.
    J. clin. oncol; 41 (30), 2023
    To provide guidance to clinicians regarding the use of systemic therapy for melanoma. American Society of Clinical Oncology convened an Expert Panel and conducted an updated systematic review of the literature. The updated review identified 21 additional randomized trials. Neoadjuvant pembrolizumab was n...
    Melanoma/inmunología, Nivolumab/uso terapéutico, Antineoplásicos Inmunológicos, Mutación/inmunología
    Texto completo

    Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

    England. National Institute for Health and Care Excellence.
    Next Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults. Commercial arrangement There is a commercial access agreement for nivolumab...
    Nivolumab/uso terapéutico, Antimetabolitos/uso terapéutico, Inhibidores de Puntos de Control Inmunológico/uso terapéutico, Neoplasias Esofágicas/terapia, Metástasis de la Neoplasia/prevención & control
    Texto completo (enlace principal)     Texto completo (enlace alternativo)